First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

被引：0
|
作者：
Tianhong Li
Patricia LoRusso
Michael L. Maitland
Sai-Hong Ignatius Ou
Erkut Bahceci
Howard A. Ball
Jung Wook Park
Geoffrey Yuen
Anthony Tolcher
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology
[2] Wayne State University,Karmanos Cancer Institute
[3] University of Chicago Medicine,Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics
[4] University of California Irvine School of Medicine,Chao Family Comprehensive Cancer Center
[5] Astellas Pharma Global Development,undefined
[6] South Texas Accelerated Research Therapies (START) Center for Cancer Care,undefined
[7] Present address: Yale Smilow Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
ASP3026; Neoplasms; ALK inhibitor; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [22] A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors
    Zhou, Caicun
    Li, Wei
    Zhang, Yiping
    Song, Zhengbo
    Wang, Yongsheng
    Huang, Dingzhi
    Ye, Feng
    Wang, Qiming
    Sun, Yinghui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Hamadani, Mehdi
    Collins, Graham P.
    Caimi, Paolo F.
    Samaniego, Felipe
    Spira, Alexander
    Davies, Andrew
    Radford, John
    Menne, Tobias
    Karnad, Anand
    Zain, Jasmine M.
    Fields, Paul
    Havenith, Karin
    Cruz, Hans G.
    He, Shui
    Boni, Joseph
    Feingold, Jay
    Wuerthner, Jens
    Horwitz, Steven
    LANCET HAEMATOLOGY, 2021, 8 (06): : E433 - E445
  • [26] A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
    Altan, M.
    Patnaik, A.
    Barve, M. A.
    Dunn, L.
    Cobb, P. W.
    Rosenberg, A.
    Sharma, S.
    Sukari, A.
    Lee, Z.
    Marcondes, M. Q.
    Zalevsky, J.
    Tagliaferri, M. A.
    Kotzin, B.
    Sacco, A. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S860 - S861
  • [27] A phase I/IIa, open-label, dose-escalation and expansion study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ107 in Chinese patients with advanced solid tumors
    Li, Jin
    Guo, Ye
    Peng, Wei
    Xue, Junli
    Zhao, Wei
    Ge, Xiaoxiao
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Li
    Zhang, Min
    Guo, Bingshi
    Wang, Liping
    Guo, Jiyuan
    Cui, Feifei
    Suo, Haiyun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [29] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [30] A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
    Tolcher, A. W.
    Falchook, G.
    Bendell, J. C.
    Ungar, D.
    Boni, J.
    Chao, G.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 176 - +
12345